This Article Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Krum, H. Search for Related Content PubMed PubMed Citation Articles by Krum, H. Social Bookmarking                         What's this?

Role of renin in heart failure and therapeutic potential of direct renin inhibition

Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, Australia

References

• Blaufarb IS, Sonnenblick EH The renin-angiotensin system in left ventricular remodeling. Am J Cardiol 1996;77:8C-16C.[CrossRef][Medline] [Order article via Infotrieve]
• Weir R., McMurray JJ Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction. Heart 2005;91(suppl 2):ii17-20.[Abstract/Free Full Text]
• Campbell DJ, Aggarwal A., Esler M., Kaye D. Beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet 2001;358:1609-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Francis GS, Benedict C., Johnstone DE et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9.[Abstract/Free Full Text]
• Brewster UC, Setaro JF, Perazella MA The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 2003;326:15-24.[Web of Science][Medline] [Order article via Infotrieve]
• Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82:1730-6.[Abstract/Free Full Text]
• Nguyen G. Renin/prorenin receptors. Kidney Int 2006; 69:1503-06.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sakoda M., Ichihara A., Kaneshiro Y. et al. (Pro)renin receptor-mediated activation of mitogen-activated protein kinases in human vascular smooth muscle cells. Hypertens Res 2007;30: 1139-46.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• de Boer RA, Pokharel S., Flesch M. et al. Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27. J Mol Med 2004;82:678-87.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Dendorfer A., Dominiak P., Schunkert H. ACE inhibitors and angiotensin II receptor antagonists. Handb Exp Pharmacol 2005;170:407-42.[CrossRef][Medline] [Order article via Infotrieve]
• Tang WH, Vagelos RH, Yee YG et al. Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002; 39(1): 70-8.[Abstract/Free Full Text]
• McMurray JJ, Ostergren J., Swedberg K. et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Cohn JN, Tognoni G.; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.[Abstract/Free Full Text]
• Pitt B., Zannad F., Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.[Abstract/Free Full Text]
• Lakkis J., Lu WX, Weir MR RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 2003;5: 408-17.[Web of Science][Medline] [Order article via Infotrieve]
• Feldt S., Batenburg WW, Mazak I. et al. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008;51:682-8.[Abstract/Free Full Text]
• Feldman DL, Jin L., Xuan H. et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008;52:130-6.[Abstract/Free Full Text]
• Mento PF, Maita ME, Murphy WR, Holt WF, Wilkes BM Comparison of angiotensin converting enzyme and renin inhibition in rats following myocardial infarction. J Cardiovasc Pharmacol 1993;21:791-6.[Web of Science][Medline] [Order article via Infotrieve]
• Pilz B., Shagdarsuren E., Wellner M. et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005;46: 569-76.[Abstract/Free Full Text]
• Kiowski W., Beermann J., Rickenbacher P. et al. Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition. Circulation 1994;90:2748-56.[Abstract/Free Full Text]
• Neuberg GW, Kukin ML, Penn J., Medina N., Yushak M., Packer M. Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure. Am J Cardiol 1991;67:63-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Waldmeier F., Glaenzel U., Wirz B. et al. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 2007;35:1418-28.[Abstract/Free Full Text]
• Seed A., Gardner R., McMurray J. et al. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur J Heart Fail 2007;9:1120-7.[Abstract/Free Full Text]
• McMurray J., Pitt B., Latini R. et al. Effects of the oral direct inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17-24.[Abstract/Free Full Text]
• Gardner RS, Ozalp F., Murday AJ, Robb SD, McDonagh TA N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003;24:1735-43.[Abstract/Free Full Text]
• Solomon S., Appelbaum E., Manning WJ et al. Effect of the direct renin inhibitor aliskiren, either alone or in combination with losartan, compared to losartan, on left ventricular mass in patients with hypertension and left ventricular hypertrophy: the Aliskiren Left Ventricular Assessment of Hypertrophy (ALLAY) Trial. Late Breaker presentation at American College of Cardiology 57th Scientific Sessions, 2008.
• ASPIRE HIGHER clinical program expands to 35,000 patients in 14 trials, the largest cardio-renal outcomes program ever. http://www.novartis.com/newsroom/mediareleases/en/2008/1228485.shtml June 17 2008.

Journal of Renin-Angiotensin-Aldosterone System, Vol. 9, No. 3, 177-180 (2008)
DOI: 10.1177/1470320308097416


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Krum, H. Search for Related Content PubMed PubMed Citation Articles by Krum, H. Social Bookmarking                         What's this?